Press releaseGlobe Newswire
Cabaletta Bio
CABA · NASDAQ
$1.61+$0.13 (+8.78%)TodayMarket closed ·
Prev close $1.48
About CABA
- Employees
- 154
- Headquarters
- PHILADELPHIA, Pennsylvania
- Listed
- Oct 25, 2019
- Sector
- Health Care
- Industry
- Biotechnology
- Website
- cabalettabio.com
CABA key statistics
- Market cap
- 272.97M
- Price-earnings ratio
- 0.00
- Dividend yield
- —
- Average volume
- 5.55M
- Volume
- 3.46M
- Open price
- $1.46
- High today
- $1.63
- Low today
- $1.45
- 52 Week high
- $4.23
- 52 Week low
- $1.39
Cabaletta Bio (CABA) at a glance
Cabaletta Bio (CABA) last traded at $1.61, with a market cap of 272.97M and a price-to-earnings ratio of 0.00.
Today the stock has traded between $1.45 and $1.63. The current price is 11.0% above the day's low and 1.2% below its high.
Volume so far is 3.46M shares, below the average of 5.55M shares a day.
Over the past year Cabaletta Bio has ranged from $1.39 to $4.23, and now sits 8% of the way up that range.
Cabaletta Bio met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.34 per share against an estimate of -$0.3807.
The average analyst price target is $13.52, 739.4% above the current price, from 5 recent ratings.
Analyst ratings
Latest rating from each analyst over the past 12 months
80%of 5 analyst ratings say Buy
- Buy80.0%
- Hold20.0%
- Sell0.0%
Price target · 10 analystsAvg $13.52
- Low
- $3.03
- Now
- $1.61
- High
- $31.50
CABA earnings
Earnings per share, reported against the analyst estimate
Beat the estimate in 4 of the last 8 quarters, by 9.7% on average.
- Q3 FY24: reported -$0.62 per share against an estimate of -$0.6081
- Q4 FY24: reported -$0.65 per share against an estimate of -$0.6434
- Q1 FY25: reported -$0.71 per share against an estimate of -$0.6675
- Q2 FY25: reported -$0.73 per share against an estimate of -$0.6627
- Q3 FY25: reported -$0.44 per share against an estimate of -$0.4814
- Q4 FY25: reported -$0.40 per share against an estimate of -$0.4702
- Q1 FY26: reported -$0.39 per share against an estimate of -$0.4095
- Q2 FY26: reported -$0.34 per share against an estimate of -$0.3807
CABA news
- Press releaseGlobe Newswire
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
- Press releaseBusiness Wire
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
- Press releaseBusiness Wire
First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform
- Press releaseGlobe Newswire
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
- Press releaseGlobe Newswire
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
- Press releaseBusiness Wire
IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms
- Vandana Singh
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
Similar companies
Companies in the same industry as Cabaletta Bio
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0003−16.67%
- SEIISharing Economy International$0.0004+100.00%
- NWGLCL Workshop Group$0.1522+27.90%
- TMSHTrans Global Assets$0.0002+0.00%
- AEFIAmerican EcoFuels$0.0007+0.00%
- CBDW1606$0.0002+0.00%
- FITYFifty 1 Labs$0.0001−66.67%
- PRSOPeraso$0.5914+54.13%
- SDSTStardust Power$0.02−23.66%
- SHFSSHF Holdings$0.0899−4.36%
- FRTTFort Technology$0.7121+32.63%
- CBDLCBD Life Sciences$0.0002−25.00%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.56+1.54%
- CTYCITY THERAPEUTICS$20.83−2.94%
- IAMIambic Therapeutics$16.01−2.02%
- AMROAmaero$5.68+1.25%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.28−0.10%
- TRXBTRex Bio$14.44−2.43%
- RTSNRetension Pharmaceuticals$16.18−0.92%
- PAXGUPine Tree Acquisition$9.98+0.00%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.18+3.39%
- ACCVAccelevation Holdings$12.31−1.44%
- RZAIROZE AI$10.28+1.28%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.